Rights Issue 2022

In order to finance the Company and accelerate the work towards an exit, primarily through continued investments in the migraine market with the support of latest study results, the Board of Directors has resolved to propose the Rights Issue. If fully subscribed, the Rights Issue is estimated to raise approximately 51.3 MSEK to Chordate Medical before costs related to the issue.

Terms and conditions of the Rights Issue

The Board of Directors’ proposal to the extraordinary general meeting includes that the Rights Issue be carried out in accordance with the main conditions set out below.

  • The right to subscribe for shares with preferential rights shall vest in those who are registered as shareholders in the Company on the record date, 20th December 2022 pro rata to their shareholdings in the Company. One (1) existing share entitles to one (1) subscription right.
  • Twenty (20) subscription rights entitles to subscription of thirteen (13) shares in the Company.  
  • The Rights Issue will increase the number of shares by maximum 102 513 047.
  • The subscription price is 0,50 SEK per share. No commission is charged.
  • The subscription period runs from December 22, 2022, up to and including January 9, 2023.
  • If not all of the shares are subscribed for through the exercise of subscription rights, the Board of Directors shall, within the scope of the maximum amount of the Rights Issue, resolve on allotment of shares subscribed for without the exercise of subscription rights, whereby allotment (i) firstly, shall be made to those who have also subscribed for shares through the exercise of subscription rights, regardless of whether the subscriber was a shareholder on the record date or not, and, in the event allotment to these cannot be made in full, allotment shall be made pro rata in relation to their subscription through their subscription rights and, where this is not possible, through a drawing of lots; and (ii) secondly, shall be made to others who have subscribed for shares in the Rights Issue without exercise of subscription rights and, in the event allotment to these cannot be made in full, allotment shall be made pro rata in relation to the number of shares each subscribed for and, where this is not possible, through a drawing of lots.
  • If the Rights Issue is fully subscribed, the Company will receive approximately 51,3 MSEK before issue costs.
  • Trading in BTA is expected to start at Nasdaq First North from 22 December 2022 until the Rights Issue is registered by the Swedish Companies Registration Office. The Rights Issue is expected to be registered towards end January 2023.

Timetable for the Rights Issue  

13 December 2022 Extraordinary general meeting

16 December 2022 Last day of trading including the right to receive subscription rights

19 December 2022 First day of trading excluding the right to receive subscription rights

20 December 2022 Record date for participation in the Rights Issue

21 December 2022 Estimated date for publication of Prospectus

22 December 2022 – 9 January 2023 Subscription period.

22 December 2022 – 3 January 2023 Trading in subscription rights.

22 December 2022 Trading in paid subscription shares (Sw. “BTA”) until the Rights Issue is registered by the Swedish Companies Registration Office (Sw. “Bolagsverket”).

11 January 2023 Expected publication of subscription result in the Rights Issue.